Individual heterogeneity screened umbilical cord-derived mesenchymal stromal cells with high Treg promotion demonstrate improved recovery of mouse liver fibrosis

Stem Cell Research & Therapy

Shuo Liu¹  Hui Yang¹  Yuanyuan Xie¹  Liudi Wang¹  Chenxu Tai¹  Bin Wang¹  Li Ling²  Libo Chen²  Shanshan Liu³ 

[1] Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, 210000, Nanjing, People’s Republic of China;Department of Endocrinology, University Health Science Center, Hua Zhong University of Science and Technology Union Shenzhen Hospital and The 6th Affiliated Hospital of Shenzhen, 518052, Shenzhen, Guangdong, People’s Republic of China;Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 210000, Nanjing, People’s Republic of China;

关键词: Cell therapy;    Umbilical cord mesenchymal stromal cells;    Heterogeneity;    Differentiation;    Immunomodulation;    Liver fibrosis;   

DOI  :  10.1186/s13287-021-02430-6

来源: Springer

【 摘 要 】

BackgroundTo investigate the heterogeneities of human umbilical cord mesenchymal stromal cells (HUCMSCs) derived from different donors and their therapeutic variations when applied to mouse liver fibrosis model.MethodsThe characteristics of HUCMSCs derived from multiple donors were comprehensively analyzed including expressions of surface markers, viability, growth curve, karyotype analysis, tumorigenicity, differentiation potentials, and immune regulation capability. Then, the HUCMSCs with distinct immunomodulatory effects were applied to treat mouse liver fibrosis and their therapeutic effects were observed.ResultsThe HUCMSCs derived from multiple donors kept a high consistency in surface marker expressions, viability, growth curve, and tumorigenicity in nude mice but had robust heterogeneities in differentiation potentials and immune regulations. In addition, three HUCMSC lines applied to mice liver fibrosis model had different therapeutic outcomes, in line with individual immune regulation capability.ConclusionThe HUCMSCs derived from different donors have individual heterogeneity, which potentially lead to distinct therapeutic outcomes in mouse liver fibrosis, indicating we could make use of the donor-variation of MSCs to screen out guaranteed general indicators of MSCs for specific diseases in further stromal cell therapy.

【 授权许可】

CC BY